{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:35:09Z","timestamp":1793781309271,"version":"4.6.1"},"reference-count":85,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Prostate Cancer Foundation Canada"},{"name":"Sullivan Urology Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Prostate cancer is the most diagnosed cancer among Canadian men, except non-melanoma skin cancers. Prostate-specific antigen (PSA) screening can enable early detection, but it is not formally recommended in Canada. Nonetheless, opportunistic screening persists, influenced by US practices and some Canadian guidelines that support screening. This study provides a detailed analysis of trends in prostate cancer incidence, mortality, stage distribution, and net survival in the context of evolving PSA screening guidelines. Prostate cancer case (1984\u20132022) and death (1984\u20132023) data were primarily from the Canadian Cancer Registry and the Canadian Vital Statistics Death database, respectively. Joinpoint regression identified incidence and mortality trends. Net survival was determined using the Pohar Perme estimator. Following the introduction of PSA screening, the prostate cancer age-standardized incidence rate among men aged 50\u201374 increased 1.8% annually until 2007 (p = 0.006) before declining at an annualized rate of \u22125.9% (p = 0.005) until 2014. Among men aged \u226575, incidence declined at \u22123.2% annually from 1992 to 2015 (p &lt; 0.001). The prostate cancer age-standardized mortality rate (ASMR) among men aged 50\u201374 fell at an annualized rate of \u22124.3% between 1994 and 2010 (p = 0.022), but the decline slowed thereafter. The ASMR among men aged \u226575 continuously declined after a peak in 1995, with the greatest change noted before 2012. From 2010 to 2017, stage IV prostate cancer incidence increased across all 10-year age groups, peaking among men aged 60\u201369 at 4.1% annually (p &lt; 0.001). Among men aged 50\u201374, the corresponding annualized increase was 3.7% (p = 0.010), while among men aged \u226575, it was 3.1% (p &lt; 0.001). Although stage IV net survival among men aged 50\u201374 increased from 49.4% in 2010\u20132011 to 56.6% in 2016\u20132017, all-stage net survival declined slightly after 2011, concurrent with a shift towards a greater proportion of stage IV cases. Prostate cancer outcomes in Canada reflect US PSA screening recommendations. Organized and thoughtful screening may represent an opportunity to decrease the rising late-stage incidence.<\/jats:p>","DOI":"10.3390\/curroncol32120669","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:35:17Z","timestamp":1764956117000},"page":"669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-8428","authenticated-orcid":false,"given":"Anna N.","family":"Wilkinson","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-6780","authenticated-orcid":false,"given":"Larry F.","family":"Ellison","sequence":"additional","affiliation":[{"name":"Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shary X.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-5541","authenticated-orcid":false,"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-3346","authenticated-orcid":false,"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Larry","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences and the Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Breau","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-8137","authenticated-orcid":false,"given":"Christopher","family":"Morash","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"Can. Med. Assoc. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline. Part III: Principles of Radiation and Future Directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1503\/cmaj.150832","article-title":"Active surveillance in Canadian men with low-grade prostate cancer","volume":"188","author":"Cristea","year":"2016","journal-title":"Can. Med. Assoc. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5489\/cuaj.5527","article-title":"Robotic surgery improves transfusion rate and perioperative outcomes using a broad implementation process and multiple surgeon learning curves","volume":"13","author":"McAlpine","year":"2018","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_6","first-page":"101180","article-title":"Is it time for Canada to revisit its approach to prostate cancer screening?","volume":"49","author":"Nguyen","year":"2025","journal-title":"Lancet Reg. Health Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1073\/pnas.79.5.1658","article-title":"Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists","volume":"79","author":"Tolis","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-5347(17)53012-8","article-title":"Impotence Following Radical Prostatectomy: Insight Into Etiology and Prevention","volume":"128","author":"Walsh","year":"1982","journal-title":"J. Urol."},{"key":"ref_15","first-page":"827","article-title":"The impact of PLCO control arm contamination on perceived PSA screening efficacy","volume":"23","author":"Gulati","year":"2012","journal-title":"Cancer Causes Control."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Hugosson","year":"2014","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.urology.2018.02.049","article-title":"New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients","volume":"118","author":"Alpert","year":"2018","journal-title":"Urology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European Study of Prostate Cancer Screening\u201423-Year Follow-up","volume":"393","author":"Hugosson","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMsb2000250","article-title":"Reconsidering the Trade-offs of Prostate Cancer Screening","volume":"382","author":"Shoag","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Biomark. Prev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E1411","DOI":"10.1503\/cmaj.220452","article-title":"Prostate cancer screening in Black men in Canada: A case for risk-stratified care","volume":"194","author":"Otiono","year":"2022","journal-title":"Can. Med. Assoc. J."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"McLaughlin, P.W., Cousins, M.M., Tsodikov, A., Soni, P.D., and Crook, J.M. (2024). Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55859-z"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.5489\/cuaj.7851","article-title":"UPDATE\u20142022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging","volume":"16","author":"Mason","year":"2022","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1503\/cmaj.140703","article-title":"Canadian Task Force on Preventive Health Care Recommendations on screening for prostate cancer with the prostate-specific antigen test","volume":"186","author":"Bell","year":"2014","journal-title":"Can. Med. Assoc. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Grossman, D.C., Curry, S.J., Owens, D.K., Bibbins-Domingo, K., Caughey, A.B., Davidson, K.W., Doubeni, C.A., Ebell, M., and Epling, J.W. (2018). Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319, 1901. Correction in JAMA 2018, 320, 2483. https:\/\/doi.org\/10.1001\/jama.2018.7453.","DOI":"10.1001\/jama.2018.3710"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00345-019-02662-5","article-title":"Evidence-based approach to active surveillance of prostate cancer","volume":"38","author":"Witherspoon","year":"2020","journal-title":"World J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.crad.2016.01.002","article-title":"Multiparametric MRI of the anterior prostate gland: Clinical\u2013radiological\u2013histopathological correlation","volume":"71","author":"Moosavi","year":"2016","journal-title":"Clin. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mayocp.2015.07.030","article-title":"Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing","volume":"91","author":"Binette","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.5489\/cuaj.6072","article-title":"Prostate specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data","volume":"14","author":"Tchir","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5489\/cuaj.4140","article-title":"Implications of prostate-specific antigen screening guidelines on clinical practice at a Canadian regional community hospital","volume":"11","author":"Webster","year":"2017","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1001\/jama.2015.14905","article-title":"Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations","volume":"314","author":"Jemal","year":"2015","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s11606-019-05561-y","article-title":"Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice","volume":"35","author":"Presti","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2211869","DOI":"10.1001\/jamanetworkopen.2022.11869","article-title":"Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer\u2013Specific Mortality","volume":"5","author":"Burgess","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.9778\/cmajo.20140079","article-title":"Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening","volume":"4","author":"Dickinson","year":"2016","journal-title":"CMAJ Open"},{"key":"ref_40","unstructured":"(2025, May 08). Statistics Canada Canadian Cancer Registry 1992 to 2022. Available online: https:\/\/www23.statcan.gc.ca\/imdb\/p2SV.pl?Function=getSurvey&Id=1556562."},{"key":"ref_41","unstructured":"Fritz, A., Percy, C., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D., and Whelan, S. (2013). International Classification of Disease for Oncology, World Health Organization. [3rd ed.]. First Revision."},{"key":"ref_42","unstructured":"World Health Organization (1977). International Classification of Diseases, World Health Organization. Volumes 1 and 2."},{"key":"ref_43","unstructured":"(2025, May 08). Statistics Canada Canadian Vital Statistics\u2014Death Database (CVS: D). Available online: https:\/\/www23.statcan.gc.ca\/imdb\/p2SV.pl?Function=getSurvey&Id=1568395."},{"key":"ref_44","unstructured":"World Health Organization (1992). International Statistical Classification of Diseases and Related Health Problems, World Health Organization. Volumes 1\u20133."},{"key":"ref_45","unstructured":"(2025, May 08). Statistics Canada Annual Demographic Estimates: Canada, Provinces and Territories 2024. Available online: https:\/\/publications.gc.ca\/site\/archivee-archived.html?url=https:\/\/publications.gc.ca\/collections\/collection_2024\/statcan\/91-215-x2024001-eng.pdf."},{"key":"ref_46","unstructured":"Brisson, J., and Pelletier, E. (2025, November 01). Evaluation of the Completeness of the Fichier des Tumeurs du Qu\u00e9bec. Available online: https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/254-evaluationcompletenessfichiertumeurs.pdf."},{"key":"ref_47","unstructured":"(2025, April 01). Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2023, Available online: https:\/\/cdn.cancer.ca\/-\/media\/files\/research\/cancer-statistics\/2023-statistics\/2023_PDF_EN.pdf."},{"key":"ref_48","unstructured":"(2025, November 17). Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2025, Available online: http:\/\/cancer.ca\/Canadian-Cancer-Statistics-2025-EN."},{"key":"ref_49","unstructured":"(Joinpoint Regression Program, 2024). Statistical Methodology and Applications Branch, Surveillance Research Program, Joinpoint Regression Program, Version 5.2.0.0."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"key":"ref_51","unstructured":"(2025, May 08). Statistics Canada. 12. Canadian Cancer Registry\u2013Standard Population Used for Age-Standardization. Available online: https:\/\/www.statcan.gc.ca\/en\/statistical-programs\/document\/3207_D12_V5."},{"key":"ref_52","unstructured":"Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., and Trotti, A. (2010). AJCC Cancer Staging Manual, Springer. [7th ed.]."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_54","unstructured":"Amin, M.B., Edge, S.B., and Greene, F. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_55","first-page":"3","article-title":"Five-year cancer survival by stage at diagnosis in Canada","volume":"34","author":"Ellison","year":"2023","journal-title":"Health Rep."},{"key":"ref_56","unstructured":"(2025, May 08). Statistics Canada Social Data Linkage Environment. Available online: https:\/\/www.statcan.gc.ca\/eng\/sdle\/index."},{"key":"ref_57","unstructured":"(2025, May 08). Statistics Canada Life tables, Canada, Provinces and Territories 1980\/1982 to 2021\/2023 (Three-Year Estimates), and 1980 to 2023 (Single-Year Estimates) (Catalogue No. 84-537-X). Available online: https:\/\/www150.statcan.gc.ca\/n1\/pub\/84-537-x\/84-537-x2024001-eng.pdf."},{"key":"ref_58","unstructured":"Statistics Canada (2025). Special Request Tabulation Completed by Demography Division, Statistics Canada."},{"key":"ref_59","first-page":"3","article-title":"Adjusting relative survival estimates for cancer mortality in the general population","volume":"25","author":"Ellison","year":"2014","journal-title":"Health Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.ejca.2011.08.010","article-title":"Estimating expected survival probabilities for relative survival analysis\u2014Exploring the impact of including cancer patient mortality in the calculations","volume":"47","author":"Dickamn","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_61","unstructured":"Dickman, P.W. (2025, May 08). Estimating and Modelling Relative Survival Using SAS. Available online: http:\/\/www.pauldickman.com\/software\/sas."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Pohar","year":"2012","journal-title":"Biometrics"},{"key":"ref_63","unstructured":"(2025, May 08). Life Table Methods. Available online: https:\/\/github.com\/FlexSurv\/repo."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.annepidem.2005.02.017","article-title":"An empirical evaluation of period survival analysis using data from the Canadian Cancer Registry","volume":"16","author":"Ellison","year":"2006","journal-title":"Ann. Epidemiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","article-title":"Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States","volume":"3","author":"Hu","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_66","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/djad205","article-title":"Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic","volume":"116","author":"Howlader","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.46747\/cfp.6805323","article-title":"Mitigating COVID-19\u2019s impact on missed and delayed cancer diagnoses","volume":"68","author":"Wilkinson","year":"2022","journal-title":"Can. Fam. Physician"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cncr.31845","article-title":"Reply to Annual Report to the Nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics","volume":"125","author":"Negoita","year":"2019","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/cncr.32604","article-title":"Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012","volume":"126","author":"Butler","year":"2020","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate Cancer Incidence and Survival, by Stage and Race\/Ethnicity\u2014United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"Mmwr Morb. Mortal. Wkly. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., and Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/82.20.1624","article-title":"Rise in prostatic Cancer Incidence Associated With Increased Use of Transurethral Resection","volume":"82","author":"Potosky","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","article-title":"Natural History of Early, Localized Prostate Cancer","volume":"291","author":"Johansson","year":"2004","journal-title":"JAMA"},{"key":"ref_75","first-page":"175","article-title":"Quantifying the role of PSA screening in the US prostate cancer mortality decline","volume":"19","author":"Etzioni","year":"2008","journal-title":"Cancer Causes Control."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11912-022-01323-y","article-title":"A Systematic Review and a Meta-analysis of Randomized Controlled Trials\u2019 Control Groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","volume":"24","author":"Napoli","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"djt367","DOI":"10.1093\/jnci\/djt367","article-title":"Individualized Estimates of Overdiagnosis in Screen-Detected Prostate Cancer","volume":"106","author":"Gulati","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ankerst, D.P., Tangen, C.M., and Thompson, I.M. (2009). Prostate Cancer Screening, Springer Science & Business Media.","DOI":"10.1007\/978-1-60327-281-0"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative Effectiveness of Alternative Prostate-Specific Antigen\u2013Based Prostate Cancer Screening Strategies: Model Estimates of Potential Benefits and Harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_80","first-page":"S2405456925001750","article-title":"Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial","volume":"29","author":"Discacciati","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.5489\/cuaj.8711","article-title":"Navigating prostate cancer screening in Canada for marginalized men through PSA screening and guidelines adherence: A call to action for policymakers","volume":"18","author":"Bandara","year":"2024","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1002\/cncr.34812","article-title":"Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system","volume":"129","author":"Kiciak","year":"2023","journal-title":"Cancer"},{"key":"ref_85","unstructured":"(2025, May 08). International Agency for Research on Cancer, World Health Organisation, Global Initiative for Cancer Registry Development: The Value of Cancer Data. Available online: https:\/\/gicr.iarc.fr\/about-the-gicr\/the-value-of-cancer-data\/."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:18:48Z","timestamp":1764958728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":85,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["curroncol32120669"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32120669","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}